Vaishali Sanchorawala, MBBS
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

MBBS, Seth G.S. Medical College



Expertise includes: AL amyloidosis - clinical trials, treatment; Stem cell transplantation; Myeloma.

Director
Boston University School of Medicine
Amyloidosis Center


Active Staff Hospital Privileges
Boston Medical Center
Medicine




A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium

A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2019 (PI)
Millennium Pharmaceuticals, Inc.

Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc.

A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.

A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2019 (PI)
Celgene Corporation

A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2018 (Co-PI)
PI: Robert W. Simms, MD
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno
12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.

Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis
04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma
03/01/2010 - 03/09/2013 (PI)
Onyx Pharmaceuticals, Inc.

Showing 10 of 13 results. Show All Results

Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 05/31/2020 (PI)
Karmanos Cancer Center

DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2019 (PI)
Janssen Scientific Affairs LLC

NEOD001-CL002
09/24/2015 - 09/30/2018 (PI)
Prothena Therapeutics Limited

Secondary Analysis of Amyloid Repository Data
09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited

PRONTO
05/13/2016 - 05/31/2017 (PI)
Prothena Therapeutics Limited



Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory light-chain (AL) amyloidosis. Blood. 2017 May 26. PMID: 28550039.
  2. Govender P, Keyes CM, Hankinson EA, O''Hara CJ, Sanchorawala V, Berk JL. Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid. 2017 Mar; 24(1):37-41.View Related Profiles. PMID: 28393574; DOI: 10.1080/13506129.2017.1301917;.
  3. Graham MS, Pudusseri A, Helgager J, Narendra DP, De Girolami U, Pinkus GS, Sanchorawala V, Miyawaki E. A Woman in Her 40s With Headache and New-Onset Seizures. JAMA Neurol. 2017 Apr 01; 74(4):476-480. PMID: 28241235; DOI: 10.1001/jamaneurol.2016.2961;.
  4. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016 Dec 12.View Related Profiles. PMID: 27965280; DOI: 10.1093/ehjci/jew298;.
  5. Uwumugambi NA, Sanchorawala V, Shelton AC, Stern L, Gordon CE. Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis. Am J Kidney Dis. 2017 Feb; 69(2):317-319.View Related Profiles. PMID: 27780577; DOI: 10.1053/j.ajkd.2016.07.037;.
  6. Prokaeva T, Spencer B, Sun F, O'Hara RM, Seldin DC, Connors LH, Sanchorawala V. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid. 2016 Dec; 23(4):214-220.View Related Profiles. PMID: 27677679.
  7. Shu J, Lo S, Phillips M, Sun F, Seldin DC, Berenbaum I, Berk JL, Sanchorawala V. Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid. 2016 Sep; 23(3):188-193.View Related Profiles. PMID: 27460276.
  8. Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016 Oct; 30(10):1979-1986. PMID: 27416985; DOI: 10.1038/leu.2016.191;.
  9. Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016 Oct; 91(10):E458-60.View Related Profiles. PMID: 27356490; DOI: 10.1002/ajh.24464;.
  10. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016 Aug 25; 128(8):1059-62.View Related Profiles. PMID: 27381904; DOI: 10.1182/blood-2016-04-710822;.
Showing 10 of 106 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 106 publications over 20 distinct years, with a maximum of 12 publications in 2011

YearPublications
19941
19981
19991
20014
20021
20035
20043
20055
20066
20075
20082
20095
20108
201112
201210
20135
20148
201510
201611
20173
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


732 Harrison Ave
Boston MA 02118
Google Map


Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department